SCHEMBL3372299

SCHEMBL3372299

CC(C)Nc1nc(-c2cccnc2)nc(-c2ccc(Cl)cc2)c1C#N

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 5/20 1.00
KDM4E B2RXH2 5/20 0.76
NPSR1 Q6W5P4 2/20 0.76
POLB P06746 1/20 0.65
KMT2A Q03164 4/20 0.65
MEN1 O00255 3/20 0.65
ALDH1A1 P00352 2/20 0.65
MAPK1 P28482 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
MAPT P10636 1/20 0.57
HTT P42858 1/20 0.57
HPGD P15428 1/20 0.47
ADORA1 P30542 3/20 0.46
ADORA2A P29274 3/20 0.44
ADORA2B P29275 1/20 0.44
PIP4K2A P48426 1/20 0.42
NPY5R Q15761 1/20 0.42
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
MAOA P21397 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3367077 0.81 RXFP1 (0.69) RXFP1KDM4ENPSR1POLBKMT2A
SCHEMBL3369871 0.79 KDM4E (1.00) RXFP1KDM4ENPSR1KMT2AMEN1
SCHEMBL20570773 0.74 KMT2A (1.00) RXFP1KDM4ENPSR1POLBKMT2A
SCHEMBL3369655 0.70 RXFP1 (0.54) RXFP1KDM4EKMT2AMEN1ALDH1A1
SCHEMBL14727731 0.70 ABCG2 (0.57) RXFP1POLBKMT2AMEN1ALDH1A1
SCHEMBL19885521 0.70 HPGD (0.74) RXFP1KDM4ENPSR1KMT2AMEN1
SCHEMBL23851984 0.69 KMT2A (0.71) RXFP1KDM4EPOLBKMT2AMEN1
SCHEMBL31591781 0.69 KMT2A (0.71) RXFP1KDM4EPOLBKMT2AMEN1
SCHEMBL23852855 0.69 KMT2A (0.71) RXFP1KDM4EPOLBKMT2AMEN1
SCHEMBL22215628 0.67 NPSR1 (0.61) RXFP1KDM4ENPSR1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1476435-B1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-06-30 EP disclosed
CN-1324015-C Pyridine and pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2007-07-04 CN disclosed
US-7022718-B2 Pyridine and pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20050143405-A1 Pyridine and pyrimidine derivatives BOEHRINGER MARKUS (CH) 2005-06-30 US disclosed
CN-1630644-A Novel pyridine and pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2005-06-22 CN disclosed
US-6867205-B2 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2005-03-15 US disclosed
EP-1476435-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-11-17 EP disclosed
WO-2003068757-A9 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2004-10-07 WO disclosed
US-20030216382-A1 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. 2003-11-20 US disclosed
WO-2003068757-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216382-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, G6PC1 RXFP1 160/4885KDM4E 1329/4885NPSR1 1776/4885
US-20050143405-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, PDXK RXFP1 439/4885KDM4E 916/4885NPSR1 1273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.